Massive MS registry study probes Long-Term safety of common drugs
NCT ID NCT05767736
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the long-term safety of two multiple sclerosis (MS) medications, Vumerity and Tecfidera, by analyzing data from over 10,000 patients in large MS registries. The goal is to track serious side effects, including infections and cancer, and compare them to other MS treatments. No new treatments are given; it simply observes existing data to better understand risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Cambridge, Massachusetts, 02142, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new rowing seat help veterans with paralysis row freely?
- Simple chin and neck exercises put to the test for MS swallowing problems
- Could a daily walk shield the brain's wiring in aging MS patients?
- Brain boot camp: can a memory-training program sharpen thinking in multiple sclerosis?
- The eyes as a window to the brain: can a simple scan monitor MS, Alzheimer's, and Parkinson's?
- Brain training without drugs: can imagining movement ease MS pain?